(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 March 2023 (16.03.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/035913 A1

(51) International Patent Classification:
A61K 31/4155 (2006.01) *A61K 31/519* (2006.01)
A61K 31/437 (2006.01) *A61P 25/00* (2006.01)

(21) International Application Number:
PCT/CN2022/113807

(22) International Filing Date:
22 August 2022 (22.08.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202111069990.0 13 September 2021 (13.09.2021) CN

(71) Applicant: **HANGZHOU HIGHLIGHTLL PHARMACEUTICAL CO., LTD** [CN/CN]; Room 301/302, No.4 BLDG, Hexiang Science & Technology Center, Qiantang District, Hangzhou, Zhejiang 310018 (CN).

(72) Inventors: **LIANG, Congxin**; Xixi Dieyuan, Bldg 25, Unit 1002, 188 Zixia St., Xihu district, Hangzhou, Zhejiang 310012 (CN). **TANG, Wei**; Wanke Qiantangfu, Bldg 9, Unit 2-2603, Shuixiang Rd., Shangcheng District, Hangzhou, Zhejiang 310020 (CN).

(74) Agent: **SINO-CREATIVITY INTELLECTUAL PROPERTY LAW FIRM**; Room 25A3-1, East Wing, Hanwei Plaza No.7 Guanghua Road, Chaoyang District, Beijing 100020 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

WO 2023/035913 A1

(54) Title: METHODS OF TREATING CNS DISORDERS

(57) Abstract: Methods relate to treat a central nervous system (CNS) disorder using a compound of Formulae (I) - (III), or a salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof. Methods of treating a CNS disorder using a composition comprising such compounds are also provided herein. The present disclosure also provides a compound of Formula (A), or a salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.